Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sutro Biopharma ( (STRO) ) has provided an update.
On March 23, 2026, Sutro Biopharma reported full-year 2025 results and announced the mutual termination of its at-the-market equity sales agreement with Jefferies, closing a potential source of incremental share issuance. The company highlighted progress across its wholly owned ADC pipeline, including completion of dosing in three cohorts of the Phase 1 trial for STRO-004 with initial data expected mid-2026, plans to advance ITGB6-targeting STRO-006 into the clinic in 2026, and an IND submission timeline this year for dual-payload PTK7 ADC STRO-227.
Sutro also reported that its Astellas-partnered TROP2-targeting dual-payload iADC entered the clinic, triggering a milestone payment, while a second Astellas program moved into IND-enabling toxicology studies. The company strengthened its balance sheet with a $110 million equity offering, extending its cash runway into at least the second quarter of 2028, as 2025 revenue rose to $102.5 million and total R&D and G&A expenses declined sharply to $207.4 million amid restructuring, positioning Sutro to fund multiple clinical and preclinical programs and reinforce its standing in the competitive ADC space.
The most recent analyst rating on (STRO) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Sutro Biopharma stock, see the STRO Stock Forecast page.
Spark’s Take on STRO Stock
According to Spark, TipRanks’ AI Analyst, STRO is a Neutral.
The score is held back primarily by weak financial fundamentals—large losses, negative cash flow, and negative equity—despite strong revenue growth and margins. Technical momentum is constructive and provides support, while valuation remains constrained by unprofitability. The Nasdaq compliance update is a modest positive but secondary to the underlying financial risks.
To see Spark’s full report on STRO stock, click here.
More about Sutro Biopharma
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on oncology, specializing in site-specific and novel-format antibody-drug conjugates. Using a proprietary cell-free protein synthesis platform, it designs single- and dual-payload ADCs intended to improve drug exposure, reduce side effects, and address treatment resistance across a broad range of solid tumors.
Average Trading Volume: 143,682
Technical Sentiment Signal: Buy
Current Market Cap: $338.9M
See more data about STRO stock on TipRanks’ Stock Analysis page.